Efanesoctocog alfa in mild hemophilia A.
Miesbach Wolfgang W, Fleck Erika E, Gatzke Florian F, Hoffmann Pascal P et al.
Pivotal trials of efanesoctocog alfa enrolled only people with severe hemophilia A; its use in nonsevere disease is limited to mixed-severity cohorts and a single case report of a woman. Mild disease differs: endogenous factor (F)VIII persists, and inhibitor risk is lifelong. To describe real-world use of efanesoctocog alfa in mild hemophilia A. We conducted a single-center, retrospective review of consecutive individuals with mild hemophilia A, including symptomatic carriers, treated between October 2025 and June 2026. FVIII activity was measured by a one-stage assay (Actin FSL). Thirteen individuals (12 men, 1 symptomatic carrier; median age, 56 years; range, 24-86) with baseline FVIII levels of 8% to 57% underwent 17 treatment episodes: 10 perioperative or procedural, 4 on-demand, and 3 prophylactic. Doses of 12 to 37 IU/kg achieved adequate hemostasis in all procedures and bleeds; 3 of 14 (2 varicose vein operations and 1 knee bleed) received a second dose. In 4 episodes, activity was 50% to 72% on days 3 to 4. Prophylaxis was administered at 26 to 40 IU/kg (median, 30) weekly or every 5 days, with trough levels of 33% to 70% (median, 61%). All injections were given on an outpatient basis. FVIII was measured in 7 of 17 episodes. No inhibitors, thrombosis, or hypersensitivity occurred. In this first series dedicated to mild hemophilia A, efanesoctocog alfa, individualized to residual FVIII, provided adequate hemostasis at doses well below the label. A single FVIII measurement on day 3 or 4, using a product-validated assay, may replace routine monitoring. Further observations require prospective study with long-term inhibitor surveillance.